Company Encyclopedia
View More
name
MeiraGTx
MGTX.US
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration.
1.946 T
MGTX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking219/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-611.42%E
    • Profit Margin-615.27%E
    • Gross Margin23.66%C
  • Growth ScoreB
    • Revenue YoY96.83%A
    • Net Profit YoY-91.31%E
    • Total Assets YoY-36.74%E
    • Net Assets YoY-142.36%E
  • Cash ScoreB
    • Cash Flow Margin-16.25%D
    • OCF YoY96.83%A
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreE
    • Gearing Ratio121.41%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Wollin Gifts 5,000 Of MeiraGTx Holdings plc [MGTX]

    Wollin Robert J Officer of MeiraGTx Holdings plc [MGTX] filed a Form 4 on November 24, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25TransactionGiftShares5,000Price$0.00ValueN/AEnding Holdings: 26,146 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    MGTX
    +5.91%
    Reuters·
    US
    MGTX
    +5.91%

    MeiraGTx Holdings plc to Participate in Evercore HealthCONx Conference

    MeiraGTx Holdings plc will participate in the 8th Annual Evercore HealthCONx Conference on December 2, 2025, presenting data on selective ROCK2 inhibitors for obesity from Graviton Bioscience. The presentation will focus on preclinical efficacy, target biology, and potential for sustained fat loss with muscle preservation. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    MGTX
    +5.91%
    Reuters·
    US
    MGTX
    +5.91%

    Bank of America Securities Sticks to Its Buy Rating for Meiragtx Holdings (MGTX)

    Bank of America Securities analyst Alec Stranahan reiterated a Buy rating for Meiragtx Holdings with a $15.00 price target. Piper Sandler also maintained a Buy rating with a $30.00 target. Stranahan, focusing on healthcare stocks, has a 4.2% average return and 56.32% success rate on recommendations.

    Tip Ranks·
    US
    MGTX
    +5.91%
    Tip Ranks·
    US
    MGTX
    +5.91%

    MeiraGTx | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 410 K

    LB filings·
    US
    MGTX
    +5.91%
    LB filings·
    US
    MGTX
    +5.91%

    Genetic medicines firm MeiraGTx misses Q3 revenue expectations, net loss widens

    MeiraGTx's Q3 revenue fell short of analyst expectations, with a significant decline from last year. The company reported a net loss of $50.5 million, driven by increased R&D expenses. MeiraGTx has entered a strategic collaboration with Eli Lilly, receiving a $75 million upfront payment. Analysts maintain a "buy" rating, with a median price target of $29.00, significantly above the current price. The company plans Phase 3 studies for Parkinson's disease and anticipates Phase 2 data for AAV-hAQP1 in 2027.

    Reuters·
    US
    MGTX
    +5.91%
    Reuters·
    US
    MGTX
    +5.91%
    © 2025 Longbridge｜Disclaimer